Results 151 to 160 of about 3,267 (182)

PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction [PDF]

Pharmacological Research, 2015
Despite recent advances in precision medicine, many molecular-based antineoplastic agents do not potentiate sustainable long term remissions, warranting the investigation of novel therapeutic strategies.
Matthew Trendowski
exaly   +4 more sources

PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy [PDF]

Journal of Radiation Research, 2016
PU-H71, a Heat shock protein 90 (Hsp90) inhibitor, has yielded therapeutic efficacy in many preclinical models and is currently in clinical trials. Carbon-ion radiotherapy (CIRT) has provided successful tumor control; however, there is still a room for ...
MATSUMOTO Yoshitaka, Tadashi Kamada, Yoshiya Furusawa   +2 more
exaly   +4 more sources

The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining

Radiotherapy and Oncology, 2016
PU-H71 is a purine-scaffold Hsp90 inhibitor developed to overcome limitations of conventional Hsp90 inhibitors. This study was designed to investigate the combined effect of PU-H71 and heavy ion irradiation on human tumor and normal cells.journal ...
Ryuichi Okayasu, Jac A Nickoloff, Shigeaki Sunada   +2 more
exaly   +2 more sources

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile [PDF]

Investigational New Drugs, 2017
Background Molecular chaperone targeting has shown promise as a therapeutic approach in human cancers of various histologies and genetic backgrounds. The purine-scaffold inhibitor PU-H71 (NSC 750424), selective for Hsp90 in epichaperome networks, has demonstrated antitumor activity in multiple preclinical cancer models. The present study was a first in-
Shivaani Kummar, Joseph Tomaszewski
exaly   +3 more sources

Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2 [PDF]

Biochimica Et Biophysica Acta - Molecular Cell Research, 2013
Heat shock protein 90 (Hsp90) has recently emerged as an attractive therapeutic target in cancer treatment because of its role in stabilizing the active form of a wide range of client oncoproteins.
Christophe Lemaire, Alexandre Prola
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Using ¹²⁴I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.

Journal of Clinical Oncology, 2013
11076 Background: PU-H71 is a Heat Shock Protein 90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU-H71) region of interest analysis and dilution principle. A microdose pilot study has shown uptake of *PU-H71 in a variety of tumors.
John F. Gerecitano, Shanu Modi, Devika Gajria, Tony Taldone, Mary Alpaugh, Erica Gomes DaGama, Mohammad Uddin, Gabriela Chiosis, Jason Stuart Lewis, Steven M. Larson, Naga Vara Kishore Pillarsetty, Komal L. Jhaveri, Brian Krichevsky, Mei Hsuan Chen, Payal Dixit, Mark Dunphy   +15 more
openaire   +1 more source

PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

Molecular and Cellular Biochemistry, 2013
This study is to determine if PU-H71, a heat shock protein inhibitor, induces killing of malignant breast cells together with treatment of tumor necrosis factor-α (TNF-α). The related molecular mechanisms were also studied. A primary mammary epithelial cell line HMEC2595 cells and the highly metastatic breast cell line MDA-MB-231, the HER2-positive BT ...
Zhuling, Qu, Shiduan, Wang, Ruyang, Teng, Xuanlong, Yi   +3 more
exaly   +3 more sources

Phase I trial of the HSP-90 inhibitor PU-H71.

Journal of Clinical Oncology, 2015
2537 Background: PU-H71 (PU) is an HSP-90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU) PET imaging, leading to a surrogate marker of intratumoral pharmacokinetics.
John F. Gerecitano, Shanu Modi, Raajit Rampal, Alexander E. Drilon, Matthew G. Fury, Mrinal M. Gounder, James J. Harding, David Michael Hyman, Anna M. Varghese, Martin Henner Voss, Fallon Olga France, Tony Taldone, Erica Gomes DaGama, Mohammad Uddin, Gabriela Chiosis, Jason Stuart Lewis, Serge K. Lyashchenko, Steven M. Larson, Christina Pressl, Mark Dunphy   +19 more
openaire   +1 more source

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2009
Triple-negative breast cancers (TNBCs) are defined by a lack of expression of estrogen, progesterone, and HER2 receptors. Because of the absence of identified targets and targeted therapies, and due to a heterogeneous molecular presentation, treatment guidelines for patients with TNBC include only conventional chemotherapy.
Ana I Robles, Lyuba Varticovski, Kamalika Moulick   +2 more
exaly   +3 more sources

Characterization of Bacillus thuringiensis ser. jordanica (Serotype H71), a Novel Serovariety Isolated in Jordan

Current Microbiology, 2003
The novel strain of Bacillus thuringiensis J112 isolated from a soil sample in Jordan was classified and characterized in terms of toxicity against dipteran and nematode larvae, crystal protein pattern, plasmid profile, and cry gene content. A new name, Bacillus thuringiensis serovariety jordanica (H serotype 71), is proposed for the reference strain ...
Hala, Khyami-Horani, Myriam, Hajaij, Jean-François, Charles   +2 more
openaire   +2 more sources